ACLS

Axcelis is a focused leader in ion-implantation equipment for semiconductor manufacturing, with particular strength in the implant-intensive power-device segment (55% of 2025 system shipment value). FY2025 was a cyclical down-year: revenue fell 17.6% to $839M (systems revenue dropped to $571M from $782.6M), operating income fell 43.4% to $119M, and diluted EPS dropped 38.2% to $3.80. Management frames this squarely as industry cyclicality — 'the semiconductor capital equipment industry is subject to cyclical swings in capital spending' — and notes its 'established cost structure does not vary significantly with changes in volume,' which is why margins fall hard when revenue declines.

The quality of the franchise and balance sheet is not in question. Gross margin held at 44.9% (up slightly from 44.7%) even through the downturn, the company is essentially debt-free with liabilities/equity of just 0.32x and $145M of cash, and it sustained R&D investment ($109M) and aggressive buybacks ($121M, roughly doubled) — shrinking shares 4.5% — signaling management's confidence in the through-cycle franchise. Axcelis also has four Purion evaluation systems placed at strategic customers, seeding future share gains.